Design: retrospective cohort studyTime period of OTC: 2006–2022Cohort: n=703 (OTC: 115, OC: 304, GnRH agonist: 175, fertility sparing treatments for gynecological cancer: 109)Age at OTC: mean age of the entire cohort: 31.8 years (range 16–40 years).Time from OTC to OTT: mean 6.17 yearsProportion of participants aged ≥18 years at EOF: not specifiedLost to FU and mortality during the study period: deceased: 15:115 (13%). Here, GNRH1 is linked to female reproductive organ cancer.